胶质瘤主动特异性免疫治疗新进展

New progress of the active-specific immunotherapy of glioma

恶性胶质瘤是中枢神经系统最常见的肿瘤,虽手术、放疗、化疗技术已有很大的进步,但其预后仍无改善。随着分子生物学和肿瘤免疫学的发展,胶质瘤的主动特异性免疫治疗策略如树突状细胞(DC)疫苗、热休克蛋白(HSP)、通过交叉免疫反应打破肿瘤诱导的免疫耐受的分子疫苗以及B7、IFN-γ、GM-CSF等前炎性免疫基因治疗等已引起人们极大的注意并显示出令人鼓舞的应用前景。本文主要围绕这几方面作一综述。

Malignant glioma is the most common primary neoplasms of central nervous system. The prognosis for patients with malignant gliomas has improved minimally despite mighty advances in surgical, radiotherapeutic, and chemotherapeutic treatment modalities. New therapeutic approaches based on the advances in molecular biology and tumor immunology are expected to establish a more effective adjuvant therapy for gliomas. The active specific strategies of glioma immunotherapy including DC vaccines, heat shock proteins (HSPs) and molecular vaccines which are used to break the tolerance induced by glioma via cross immunologic reactions and the strategies of immune gene therapy involving proinflammatory factors such as B7, IFN-γ, GM-CSF have gained more attention and showed a promising prospect. In this paper, we reviewed the latest progress in these aspects.